Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Current Leases (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Current Leases for 4 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Current Leases fell 0.64% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 0.64% year-over-year, with the annual reading at $1.9 million for FY2025, 0.64% down from the prior year.
  • Current Leases hit $1.9 million in Q4 2025 for Taysha Gene Therapies, up from $1.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $1.9 million in Q4 2024 to a low of $1.5 million in Q4 2022.
  • Historically, Current Leases has averaged $1.7 million across 4 years, with a median of $1.7 million in 2025.
  • Biggest five-year swings in Current Leases: increased 18.01% in 2024 and later fell 8.1% in 2025.
  • Year by year, Current Leases stood at $1.5 million in 2022, then grew by 8.22% to $1.6 million in 2023, then grew by 14.03% to $1.9 million in 2024, then dropped by 0.64% to $1.9 million in 2025.
  • Business Quant data shows Current Leases for TSHA at $1.9 million in Q4 2025, $1.7 million in Q3 2025, and $1.7 million in Q2 2025.